Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2011, Article ID 247959, 21 pages
Review Article

Evolution of 𝜷 -Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation

School of Medicine, University of Virginia, Charlottesville, VA 22102, USA

Received 29 May 2011; Accepted 8 August 2011

Academic Editor: Andrew Posselt

Copyright © 2011 Cyrus Jahansouz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Diabetes mellitus remains one of the leading causes of morbidity and mortality worldwide. According to the Centers for Disease Control and Prevention, approximately 23.6 million people in the United States are affected. Of these individuals, 5 to 10% have been diagnosed with Type 1 diabetes mellitus (T1DM), an autoimmune disease. Although it often appears in childhood, T1DM may manifest at any age, leading to significant morbidity and decreased quality of life. Since the 1960s, the surgical treatment for diabetes mellitus has evolved to become a viable alternative to insulin administration, beginning with pancreatic transplantation. While islet cell transplantation has emerged as another potential alternative, its role in the treatment of T1DM remains to be solidified as research continues to establish it as a truly viable alternative for achieving insulin independence. In this paper, the historical evolution, procurement, current status, benefits, risks, and ongoing research of islet cell transplantation are explored.